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Background: The choice of tetanus prophylaxis for patients with wounds depends on obtaining their
vaccination history, which has been demonstrated to be unreliable. Use of a rapid immunoassay (Te´tanos
Quick Stick, the TQS), combined with knowledge of certain demographic characteristics, may improve the
evaluation of tetanus immunity and thus help to avoid inadequate prophylactic measures and reduce costs.
Objectives: To evaluate the contribution of the TQS in the choice of tetanus prophylaxis and to perform a cost-
effectiveness analysis. The final aim was to define the place of the TQS in a modified algorithm for assessment
of tetanus immunity in the emergency department.
Method: In this Belgian prospective, double-blind, multicentre study, 611 adult patients with a wound were
included; 498 (81.5%) records were valid. The TQS test was performed by a nurse before the vaccination
history was taken and the choice of prophylaxis was made, using the official algorithm (Belgian Superior
Health Council), by a doctor who was unaware of the TQS result.
Results: The prevalence of protective anti-tetanus immunity was 74.1%. Immunity was lower in older patients
and in female patients. The TQS was a cost-effective tool for patients presenting with a tetanus-prone wound
and considered from the vaccination history to be unprotected. Use of the TQS would have improved
management in 56.9% (95% CI 47.7% to 65.7%) of patients by avoiding unnecessary treatments, leading to a
reduction in the mean cost per patient (J10.58/patient with the TQS versus J11.34/patient without). The
benefits of the TQS use were significantly greater in patients ,61 years old: unnecessary treatment would
have been avoided in 76.9% (95% CI 65.8% to 85.4%) of cases and the mean cost per patient reduced to
J8.31.
Conclusion: In selected patients, the TQS is a cost-effective tool to evaluate tetanus immunity. An algorithm is
proposed for ED assessment of tetanus immunity integrating age and the TQS result.
D
espite the wide availability of an excellent vaccine,
tetanus is still a prevalent disease. The estimated
incidences in the World Health Organization European
region and the USA in the 1990s were 0.8 and 0.16 per million
inhabitants, respectively,1 2 but it is believed that there is
significant underreporting.3 4 In industrialised countries, most
cases of cases occur among non-immunised patients after an
acute wound,4–6 and approximately 30–40% of them are fatal.6 7
Tetanus prophylaxis is the cornerstone of disease prevention,
and primary care providers have an important role to play. The
decision whether or not to give prophylaxis currently depends
on the characteristics of the wound (low or high risk) and on
evaluation of the patient’s immunity based on the vaccination
history.8 9 However, vaccination history is unreliable in evalua-
tion of tetanus immunity10–12 and thus prophylaxis may be
suboptimum in relation to actual immunity. Although over-
immunisation increases costs and risks of secondary effects
unnecessarily, underimmunisation puts the patient at risk of
contracting tetanus.
Recently, an immunochromatography-based test (Te´tanos
Quick Stick; TQS) has been marketed, making bedside
semiquantitative evaluation of anti-tetanus immunity possible.
We and others have shown that the TQS is a reliable and
effective tool for the evaluation of immunity to tetanus in the
emergency department (ED).10 13 14 To our knowledge, however,
no cost–benefit analysis of TQS use has previously been
performed. This multicentre study was designed to investigate
the cost-effectiveness of the TQS for the choice of tetanus
prophylaxis for patients presenting in the ED with a wound.
Because anti-tetanus immunity has previously been shown to
be related to age, sex, and birthplace,10 15 16 these demographic
features were included in the analysis.
Finally, taking into account these results as well as those of
our previous study,10 we were able to define the place of the
TQS in a modified algorithm for management of patients
presenting to the ED with a wound.
METHODS
Survey design
This multicentre, prospective, double blind study was con-
ducted in five EDs (three university-affiliated hospitals and two
local hospitals) located in urban or rural areas of the three
regions of Belgium (Brussels, Flanders and Wallonia) (table 1).
The ethics committee of each participating centre approved
the study, and the ethics committee of Erasme University
Hospital (Brussels) was designated as the organising commit-
tee.
Selection of the participants and data collection
Consecutive adult patients were included if they attended the
participating EDs with a wound or any other condition
associated with the need to assess tetanus prophylaxis.
Exclusion criteria were age ,18 years, prior inclusion in the
same study, and inability to provide a history (eg, psychiatric
disease, dementia or confusion). In total, 611 adult patients
Abbreviations: ED, emergency department; ELISA, enzyme linked
immunosorbent assay; NPV, negative predictive value; PPV, positive
predictive value; TD, tetanus combined with diphtheria anatoxin vaccine;
TQS, Te´tanos Quick Stick; TT, tetanus toxoid
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who attended the five EDs between May and October 2006 were
included; 498 (81.5%) records were suitable for analysis (fig 1).
The TQS test was performed by a nurse before the vaccination
history was taken by another nurse or a doctor, who were
unaware of the TQS result. The choice of prophylaxis was made
by the doctor (who again was unaware of the TQS result), using
the official algorithm defined by the Belgian Superior Health
Council.8 A patient was considered to be protected if they had
undergone a complete vaccination programme (three doses of
tetanus anatoxin) and their last booster had been administered
within the previous 10 years. A wound that met at least one of
the following criteria was considered at risk of tetanus: wound
care delayed for .6 hours, depth .1 cm, burn, abrasive
wound, chronic wound, wound contamination (bite, scratch,
stain, foreign bodies, faeces), presence of necrotic tissue, or
signs of infection. Presentation of a vaccination card or any
other official document related to the patient’s vaccination
history was noted in the medical record. Sociodemographic
characteristics (age, sex and place of birth) were systematically
recorded.
Evaluation of immunity by the Te´ tanos Quick Stick
Immunity against tetanus was evaluated by the TQS (Gamma,
Angleur, Belgium). This semiquantitative test, designed for
bedside use only, requires one drop of blood that can be taken
by finger prick, and detects anti-tetanus toxoid (anti-TT)
antibody using immunochromatography. There are no contra-
indications to this test. The principle and procedure have been
described in detail elsewhere.13
The tests were performed on whole blood and were
interpreted after 10 minutes in accordance with the manufac-
turer’s recommendation. The detection threshold asserted by
the company is 0.2 IU/mL on whole blood. Validation of the
TQS test was performed in a previous recent study performed
by our group.10 Compared with ELISA, which is a reference
method for determination of anti-TT antibody, the negative
Table 1 Description of investigative EDs and study group
Total
Emergency department identity number
p Value*1 2 3 4 5
Investigative ED
Location (area, region) Urban, Brussels Urban, Flanders Urban, Flanders Rural, Wallonia Rural, Wallonia
University-affiliated Yes Yes No Yes No
Study group
Patients with data suitable for analysis (n) 498 100 101 98 106 93
Mean (SEM) age 43.8 (0.78) 44.1 (1.82) 42.6 (1.73) 47.5 (1.83) 43.2 (1.70) 41.6 (1.68) NS
Male/female (%) 69.9/30.1 74.0/26.0 74.2/25.8 63.3/36.7 67.9/32.1 69.9/30.1 NS
Native/not native to Belgium (%) 86.4/13.6 80.6/19.4 89.1/10.9 88.4/11.6 85.8/14.2 88.0/12.0 NS
Prevalence of anti-tetanus immunity (%) 74.1 68.0 78.2 58.2 84.0 81.7 ,0.001*
ED, emergency department; NS, non-significant.
*Difference between groups.
Figure 1 Study design.
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predictive value (NPV) of the TQS was 77.2%, which was
significantly better than vaccination history (45.8%, p,0.0001)
for determination of tetanus immunity, and the positive
predictive value (PPV) was 92.1%, which differed only slightly
from vaccination history (81.8%, p = 0.04) (see appendix 1).
A training course was organised for the ED nurse team before
starting the study. Results (positive or negative) were recorded
in the patient’s medical records. All tests were carefully
preserved. To avoid the variability of interpretation inherent
in using different operators, a second interpretation of the tests
was systematically performed by the most experienced main
investigator (MS) who found that 22 tests (4.4%) interpreted as
negative were actually positive.
Cost–benefit analysis
The cost of the tetanus prophylaxis based on the vaccination
history was compared with the cost of prophylaxis based on the
TQS result. Because the PPV of the TQS is as high as vaccination
history (appendix 1) in the evaluation of immunity, this cost–
benefit analysis was not performed in patients claiming to be
protected against tetanus.
The unit prices of tetanus-specific immunoglobulin (J7.46;
Tetabulin, Baxter, Deerfield, Illinois, USA), tetanus vaccine
(J3.88, tetanus combined with diphtheria anatoxin (TD);
Tedivax, GlaxoSmithKline, Genval, Belgium) and TQS (J5.70;
Gamma, Angleur, Belgium) used were those charged (including
value added tax at 21%) for in-hospital use in Belgium. In
practice, the cost of prophylaxis is shared between the patient
and the social insurance system, whereas the cost of the TQS is
currently charged to the patient.
Statistical analysis
Data were analysed by descriptive statistics (mean (SEM),
frequencies and 95% CI). One way analysis of variance or the x2
test were performed to determine the differences between
groups, and p,0.05 was considered significant. All statistical
analyses were performed using SPSS V.12.0 (SPSS, Chicago, IL,
USA)
RESULTS
Prevalence of immunity against tetanus
The prevalence of protective immunity against tetanus was
evaluated by calculating the percentage of patients with a
positive TQS. Overall, 74.1% (95%CI 70.3% to 77.9%) of the
patients were protected, but this proportion varied significantly
among the different EDs (range 58.2% to 84.0%) (table 1). As
we previously found that age, sex and birthplace are good
predictive factors for the presence of tetanus immunity, we
investigated whether differences in these demographic features
could explain such variations in the seroprevalence rate.
Interestingly, there were no significant differences among
groups in mean age, sex ratio, or proportion of patients not
native to Belgium (table 1).
These results suggest that other factors influence the
prevalence of tetanus immunity. For example, patients attend-
ing the ED of a hospital located in a rural area were generally
better protected than those attending the EDs of urban
hospitals (82.9% vs 68.2%, p,0.001). The presence of protective
immunity was clearly related to age and sex but not to
birthplace. The prevalence of immunity decreased sharply with
increasing age, from 87.7% among patients aged 31–45 years to
21.2% in those aged .76 years (fig 2). Interestingly, the best
seroprotection rate was observed in patients aged 31–45 years,
rather than younger patients. When all groups of all ages were
merged, women were significantly less protected than were
men (63.3% vs 78.7%, p,0.001), but this sex difference in
protection was not statistically significant within each age
category.
Evaluation of tetanus immunity by vaccination history
versus the TQS
Based on the vaccination history, the patients were separated
into two groups, protected and unprotected (including
‘‘unknown’’) and need for prophylaxis was determined
accordingly.
Of 169 patients who were classified as unprotected, 97
(57.4%) in fact had a protective antibody level (fig 1). This
proportion was similar for patients presenting with tetanus-
prone (70/123, 56.9%) and non-tetanus-prone (27/49, 58.7%)
wounds. For these patients, evaluation of immunity by the TQS
instead of by vaccination history would have changed the
choice of prophylaxis in most cases. In contrast, 271 of the 329
patients (82.4%) considered as protected according to the
vaccination history had a positive TQS result.
Only 10.2% of patients had a vaccination card. In most cases,
therefore, the medical team had no objective evidence of
vaccination status and had to select prophylaxis based only on
the reported vaccination history.
Cost–benefit analysis of the TQS
We then investigated the effect of TQS use on the cost of the
prophylactic treatment. As stated, only patients considered as
unprotected (unknown vaccination history, incomplete vacci-
nation programme, or last booster .10 years previously) would
be able to benefit from the TQS. The analysis was thus limited
to this category of patients. Because administration of tetanus-
specific immunoglobulin is indicated only for tetanus-prone
wounds, patients presenting with tetanus-prone and non-
tetanus-prone wounds were analysed separately. For tetanus-
prone wounds and combining all age groups, use of the TQS
would have avoided unnecessary treatment in 56.9% (95% CI
47.7% to 65.7%) of cases (table 2), leading to a reduction in the
mean cost per patient (J10.58/patient with the TSQ vs J11.34/
patient without). Because patients aged .61 years were much
better protected, the same analysis was performed in this
selected group (table 2). Unnecessary treatment would have
been avoided in 76.9% (95% CI 65.8% to 85.4%) of this group of
patients. As expected, the financial gain with use of the TQS
was significantly (p,0.001) higher in this group than in
patients of all ages (J8.31/patient vs J10.58/patient respec-
tively). For non-tetanus-prone wounds, despite allowing
unnecessary treatment to be avoided in 58.7% (95% CI 44.4%
to 72.9%) of patients, use of the TQS would not have been
cost-effective, whatever the patient’s age (J7.30 with the TQS
vs 3.88J/patient without; table 2). This finding was not
Figure 2 Prevalence of immunity against tetanus according to age and
sex.
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surprising, considering the higher cost of specific immunoglo-
bulin compared with the TT (and diphtheria) vaccine.
In conclusion, the use of the TQS has a cost benefit only for
patients presenting with tetanus-prone wounds and considered
from the vaccination history to be unprotected (table 3).
DISCUSSION
Lack of tetanus immunity is the main cause of the persistence
of tetanus, ‘‘the inexcusable disease’’,17 in developed countries,
and is common among patients presenting to the ED.11 18
According to the TQS results, 25.9% of patients with a
tetanus-risk wound had no protective antibody level. Because
the spores of Clostridium tetanii are ubiquitous, exposure is
frequent and difficult to prevent. Passive or active immunisa-
tion by immunoglobulin or vaccine, respectively, is the most
efficient way to prevent the disease.
The increased number of cases of tetanus observed among
geriatric patients4 9 19 is not surprising; this study, like previous
studies,10 15 16 20 show that the level of protective antibodies
decreases with age. There may be several reasons for this
observation: lack of systematic vaccination before the late
1950s, increased life expectancy without administration of the
recommended tetanus booster, and possibly a deficient
immune response to vaccine associated with immunosenes-
cence.21 Whatever the underlying reasons, age is an important
variable to include in the assessment of tetanus immunity, as
has already been suggested.11–13
The TQS represents a useful tool in the evaluation of tetanus
immunity, but the economic benefit of such a tool needed to be
investigated. Indeed, the cost of the TD vaccine is less than the
price of the TQS; however, immunoglobulins are more
expensive. In this double-blind study, we compared the cost
of prophylaxis chosen on the basis of vaccination history versus
that based on the TQS result. Because the NPV (but not the
PPV) of the TQS is higher than that for vaccination history, the
cost analysis was performed only for patients believed to be
unprotected. As expected, use of the TQS enabled the mean cost
per patient to be decreased only for those requiring immuno-
globulin, namely, those with a tetanus-prone wound. The cost
saving was significantly increased for patients aged ,61 years,
although the same low NPV of the vaccination history is
observed in this age category, the proportion of immunised
patients was higher. For tetanus-prone wounds, 56.9% of
patients claiming to be unprotected actually had a positive the
TQS. Interestingly, this proportion is very similar to the 54.2%
that we found in our previous study,10 suggesting that it is
reproducible. According to the results, the treatment given
(immunoglobulin and TD) was unnecessary in at least 47.7%,
and potentially in 65.7%, of these patients. This proportion was
increased to 76.9% in patients aged ,61 years. Applying these
results globally across Belgium, a crude calculation estimates
the cost savings related to the TQS as between 300 000 and
400 000 euros per year (see appendix 3). Importantly, as well as
the economic consequences, excessive administration of
immunoglobulins and anatoxins increases the risk of adverse
effects. Clinical features associated with overimmunisation
induced by anatoxin range from local reaction at the injection
site to serum disease.22 23 Immunoglobulins are biologically
active blood byproducts, and their use may be associated with
possible transmission of pathogenic agents.24
Our results clearly demonstrate that the TQS is a useful and
cost-effective tool in a group of patients defined by age and
vaccination history. A conservative approach to the manage-
ment of tetanus prophylaxis would be to increase treatment
among older, less immunised patients, and a rational approach
would be to better identify younger patients who are more
likely to be immunised and who are eligible for treatment with
immunoglobulin and TD. Following this logic, we propose a
modified algorithm for management of tetanus prophylaxis
based on the characteristics of the wound, the age, the
vaccination history and the TQS result (fig 3). The cut-off of
60 years was chosen on the basis of current epidemiological
data but will need to be re-evaluated in the future because of
the difficulty in measuring the influence of extrinsic factors,
such as the end of World War II and systematic vaccination, on
the prevalence of immunity.
Given these data, at least partial coverage of the cost of the
test by the Belgian social insurance system should be
considered. This algorithm needs to be tested in a future
large-scale prospective study, particularly to evaluate the
feasibility of its use in clinical practice.
Table 2 Cost analysis of the TQS use among patients with unknown or unprotected
vaccination history*












Patients with tetanus-prone wound, all ages
Vaccination history 100 — 11.34
TQS 43.1 56.9 (47.7 to 65.7) 10.58
Patients with tetanus-prone wound aged ,61 years
Vaccination history 100 — 11.34
TQS 23.1 76.9 (65.8 to 85.4) 8.31
Patients with non-tetanus-prone wound, all ages
Vaccination history 100 — 3.88
TQS 41.3 58.7 (44.4 to 72.9) 7.30
*Incomplete vaccination programme or last booster .10 years previously.
Price in euros, taxes included.






protected Partially protected*/fully protected
Yes Mean cost/patient
reduced
Not useful because the positive
predictive value of vaccination history is




*Complete vaccination programme with last booster 5–10 years previously.
Complete vaccination programme with last booster ,5 or ,10 years
previously in presence of tetanus-prone or non-tetanus-prone wound,
respectively.
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In conclusion, the choice of tetanus prophylaxis in patients
with wounds is often not related to the true immunity of the
patient. The practical and harmful consequences are that
unnecessary and expensive treatments are given to young
patients and poor anti-tetanus immunisation is provided for
older patients. The rationale for use of the TQS use is the cost
benefit, and age is a key factor to include in the assessment of
tetanus immunity. A modified algorithm is proposed that
would improve the choice of tetanus prophylaxis and, at the
same time, allow substantial economic savings.
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APPENDIX 1
APPENDIX 2
RESULTS IN A NUTSHELL
N Overall, 74.1% (95% CI 70.3% to 77.9%) of patients had
protective anti-tetanus immunity.
N The prevalence of immunity differed significantly among
the participating EDs despite lack of significant
differences in the demographic characteristics of the study
population.
N The prevalence of immunity decreased with increasing age
and was lower in women than in men.
N Most patients who were unprotected according to their
vaccination history in fact had a protective level of anti-TT
antibody by the TQS.
N The TQS has cost benefits for patients presenting with a
tetanus-prone wound and with an ‘‘unknown’’ or ‘‘pro-
tected’’ vaccination history.
N The economic gain is significantly increased for patients
(60 years.
APPENDIX 3
A PROJECTION: THE CASE IN BELGIUM
N Based on consumption of 55 000 doses of c-globulin in 2006
for , 106 inhabitants, use of the TQS would have saved a
minimum of 47.7% (n = 26 235) and a maximum of 65.7%
(n = 36 135) of treatments.
N Considering the usual and recommended administration of
TD (J3.88) in combination with c-globulin (J7.46), the
estimated financial saving is J297 05 to J409 771.
Table A1 Comparison between vaccination history and the
TQS for anti-tetanus immunity evaluation
History TQS p Value
Concordance (kappa) 0.27 0.71
Sensitivity (%) 60.3 85.3 ,0.0001
Specificity (%) 73.3 87.2 0.065
Positive predictive value (%) 81.8 92.1 0.039
Negative predictive value (%) 45.8 77.2 ,0.0001
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